Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Amalgamated Bank

Amalgamated Bank decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 4.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,557 shares of the biopharmaceutical company’s stock after selling 912 shares during the quarter. Amalgamated Bank’s holdings in Royalty Pharma were worth $499,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Keene & Associates Inc. lifted its holdings in shares of Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 370 shares during the period. Blue Trust Inc. lifted its holdings in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares during the period. Sanctuary Advisors LLC lifted its holdings in shares of Royalty Pharma by 0.9% during the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock worth $1,068,000 after purchasing an additional 388 shares during the period. Aurora Investment Counsel lifted its holdings in shares of Royalty Pharma by 1.0% during the third quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock worth $1,427,000 after purchasing an additional 512 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Royalty Pharma by 31.4% during the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 590 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $41.60.

Royalty Pharma Trading Down 1.6 %

Shares of NASDAQ:RPRX opened at $33.32 on Wednesday. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The company has a market capitalization of $19.21 billion, a PE ratio of 22.98, a PEG ratio of 2.31 and a beta of 0.49. The business has a 50 day moving average of $30.40 and a two-hundred day moving average of $28.28. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.64%. Royalty Pharma’s payout ratio is 60.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.